Massive Bio
Artificial Intelligence

Our Artificial Intelligence (AI) based technology precisely identifies and matches patients clinical trials in community practices. Our proprietary technology is comprised of:

  • Natural Language Processing for medical records, molecular diagnostics test results and clinical trial protocols; oncology proprietary ontology with 50, 000 elements specific to detailed oncology trial pre-screening

  • Machine learning technology for scaled pre-screening; prescreening in the matter of seconds instead of hours

  • Real world data platform that generates insights for drug discovery and development; thousands of full patient longitudinal journey for rapid insights

  • AI powered patient identification technology; patients are found for pre-screening across the globe in the matter of seconds if they are in Massive Bio’s patient and provider network for trials

Next Generation Oncology Clinical Trials Platform

Massive Bio Controls Patient Enrollment Value Chain in Oncology

Support team
Patient acquisition & on-boarding

Virtual Patient Contact Center

Patients are onboarded from providers’ call centers, online marketing efforts, advocacy groups and Massive Bio’s proprietary SYNERGY-AI /registry with cutting edge technology. Specially trained patient advocates provide patient education and engagement before escalation to the case management team.

Support team
Patient pre-screening

Clinical Trial Matching System (CTMS)

Patients are pre-screened with AI based technology for trials and advanced care options if trial is not available. Sub-specialist and case management support are provided for operationalization of recommendations.

Support team
Site mobilization and enrollment

Just In Time (JIT) Hub

Best sites are identified with AI based global patient identification registry, PI is onboarded, and site is activated with cutting edge technology.

Support team
Drug discovery

Real World Insights

Patients clinical, genomic and outcomes information are captured, and synthetic control arm, biomarker discovery and off-label indication expansion studies are developed with AI based technology.

Oncology Clinical Trials Are Broken

Particularly patient access from community practices (i.e. Non-NCI designated cancer centers) where 85% of cancer patients are treated

Current state 3% Enrollment rate

  • Limited technology and infrastructure

  • Limited patient engagement

  • Disconnected stakeholders

  • Significant operational inefficiency

Mirage
Future state 20% Enrollment rate

  • End-to-end technology platform

  • Virtual infrastructure as applicable

  • Engaged patients

  • Stakeholder orchestrator Massive Bio

Future state
Massive Bio Recognition By The Healthcare Community
  • Becker's Hospital Review, 2019

    100+ artificial intelligence companies know in healthcare

  • Thrive Global, 2018

    CEO selected 99 "Limit Breaking Female Founders"

  • Philadelphia Inquirer, 2019

    CMO selected "Influencer in Healthcare" in the category of Outstanding Healthcare Provider

  • McDermott, 2019

    CEO selected Digital Health Pioneer

We’re Here To Help

For close to 10,000 patients that have reached out to our patient contact center

55%

of the patients are eligible at least one trial

12%

of the patients are enrolled

Comprehensive Services To Enterprises
Generating Value To 4Ps: Pharma, Provider, Patient and Payer
Pharmaceutical Companies and CROs
Providers
Patients
Payers
Patient Recruitment
AI Based Prescreening For Sites
Virtual Tumor Board (VTB)
Clinical Trial Matching
Site Selection Traditional
AI Based prescreening For Outreach Facilities
VTB/Comprehensive Case Review
Site Selection JIT
Real World Data
Real World Data
JIT Site Activation Through Partners
Strategic Pipeline Assessment
Real World Data
Ready to dive in?
Start your cancer journey today.